Compare · NVO vs TRAX
NVO vs TRAX
Side-by-side comparison of Novo Nordisk A/S (NVO) and First Tracks Biotherapeutics Inc. (TRAX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and TRAX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.82B, about 291.3x TRAX ($631.0M).
- Over the past year, NVO is down 34.2% and TRAX is down 1.1% - TRAX leads by 33.2 points.
- TRAX has been more active in the news (20 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 5 for TRAX).
- Company
- Novo Nordisk A/S
- First Tracks Biotherapeutics Inc.
- Price
- $41.18+6.93%
- $18.38-3.26%
- Market cap
- $183.82B
- $631.0M
- 1M return
- +13.32%
- -1.08%
- 1Y return
- -34.24%
- -1.08%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 5
- 20
- Recent ratings
- 25
- 5
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S
Latest TRAX
- Wedbush initiated coverage on First Tracks Biotherapeutics with a new price target
- Leerink Partners initiated coverage on First Tracks Biotherapeutics with a new price target
- SEC Form 3 filed by new insider Tamboli Ajim
- SEC Form 4 filed by Chief Financial Officer Tamboli Ajim
- Analyst initiated coverage on First Tracks Biotherapeutics with a new price target
- SEC Form SCHEDULE 13G filed by First Tracks Biotherapeutics Inc.
- SEC Form 4 filed by Ecor1 Capital, Llc
- SEC Form 3 filed by new insider Ecor1 Capital, Llc
- SEC Form 3 filed by new insider Stone Benjamin
- SEC Form 4 filed by Ware J. Anthony